Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology
Thomas M Gorter, Dirk J van Veldhuisen, Johann Bauersachs, Barry A Borlaug, Jelena Celutkiene, Andrew J S Coats, Marisa G Crespo-Leiro, Marco Guazzi, Veli-Pekka Harjola, Stephane Heymans, Loreena Hill, Mitja Lainscak, Carolyn S P Lam, Lars H Lund, Alexander R Lyon, Alexandre Mebazaa, Christian Mueller, Walter J Paulus, Burkert Pieske, Massimo F Piepoli, Frank Ruschitzka, Frans H Rutten, Petar M Seferovic, Scott D Solomon, Sanjiv J Shah, Filippos Triposkiadis, Rolf Wachter, Carsten Tschöpe, Rudolf A de Boer, Thomas M Gorter, Dirk J van Veldhuisen, Johann Bauersachs, Barry A Borlaug, Jelena Celutkiene, Andrew J S Coats, Marisa G Crespo-Leiro, Marco Guazzi, Veli-Pekka Harjola, Stephane Heymans, Loreena Hill, Mitja Lainscak, Carolyn S P Lam, Lars H Lund, Alexander R Lyon, Alexandre Mebazaa, Christian Mueller, Walter J Paulus, Burkert Pieske, Massimo F Piepoli, Frank Ruschitzka, Frans H Rutten, Petar M Seferovic, Scott D Solomon, Sanjiv J Shah, Filippos Triposkiadis, Rolf Wachter, Carsten Tschöpe, Rudolf A de Boer
Abstract
There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.
Keywords: Biomarkers; Heart failure; Heart failure with preserved ejection fraction; Pulmonary hypertension; Right ventricular function.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.
Source: PubMed